<DOC>
	<DOCNO>NCT00259402</DOCNO>
	<brief_summary>- To determine activity efficacy schema specify dose regimen - To determine safety tolerability oxaliplatin-cisplatin 5FU</brief_summary>
	<brief_title>Oxaliplatin Esophagus Cancer ( Advanced ) 1st Line</brief_title>
	<detailed_description />
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>ECOG 01 Patients histologically proven epidermoid carcinoma adenocarcinoma esophagus stomach , unresectable metastatic disease ; No previous treatment chemotherapy radiotherapy Measurable lesion ( uni bidimensional ) Creatinin clearance &lt; 50 mL/min Total bilirubin &gt; 1.5*ULN ( Upper Limit Normal ) AST/ALT &gt; 2.5*ULN Total White Blood Cell &lt; 1.500.000/mL Platelet count &lt; 100.000.000/mL symptomatic sensitive peripheral neuropathy pregnant breastfeed woman The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>